Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
    3.
    发明授权
    Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases 失效
    支链氨基酸依赖性氨基转移酶抑制剂及其在治疗神经退行性疾病中的应用

    公开(公告)号:US06809119B2

    公开(公告)日:2004-10-26

    申请号:US10304803

    申请日:2002-11-26

    IPC分类号: A61K3118

    CPC分类号: C07C311/49 C07C2601/14

    摘要: The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

    摘要翻译: 本发明涉及BCAT抑制剂及其用于治疗或预防与中风,缺血,CNS创伤,低血糖和手术相关的神经元损失以及治疗包括阿尔茨海默病,肌萎缩性侧索硬化,亨廷顿病和唐氏综合征的神经变性疾病的治疗或治疗 或预防兴奋性氨基酸过度刺激的不良后果,治疗焦虑症,精神病,抽搐,氨基糖苷类抗生素诱发的听力损失,偏头痛,慢性疼痛,神经性疼痛,帕金森病,糖尿病性视网膜病变,青光眼,CMV视网膜炎,尿失禁 ,阿片类药物耐受或戒断,诱导麻醉以及增强认知功能。

    Tetrahydroquinoxaline dopamine D4 receptor antagonists
    5.
    发明授权
    Tetrahydroquinoxaline dopamine D4 receptor antagonists 失效
    四氢喹喔啉多巴胺D4受体拮抗剂

    公开(公告)号:US5885994A

    公开(公告)日:1999-03-23

    申请号:US35244

    申请日:1998-03-05

    CPC分类号: C07D401/12 C07D241/42

    摘要: This invention relates to compounds that are antagonists of dopamine D4 receptors having Formula I below ##STR1## This invention also relates to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.

    摘要翻译: 本发明涉及作为下文具有式I的多巴胺D4受体的拮抗剂的化合物。本发明还涉及使用作为多巴胺D4受体的拮抗剂的化合物以及含有可药用组合物的药学上可接受的组合物来治疗精神病和精神分裂症的方法 多巴胺D4受体拮抗剂。